Surgery of non-spinal skeletal metastases in renal cell carcinoma by Ratasvuori, Maire et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iort20
Download by: [University of Helsinki] Date: 18 April 2016, At: 02:28
Acta Orthopaedica
ISSN: 1745-3674 (Print) 1745-3682 (Online) Journal homepage: http://www.tandfonline.com/loi/iort20
Surgery of non-spinal skeletal metastases in renal
cell carcinoma
Maire Ratasvuori, Niko Sillanpää, Rikard Wedin, Clement Trovik, Bjarne H
Hansen & Minna Laitinen
To cite this article: Maire Ratasvuori, Niko Sillanpää, Rikard Wedin, Clement Trovik, Bjarne
H Hansen & Minna Laitinen (2016) Surgery of non-spinal skeletal metastases in renal cell
carcinoma, Acta Orthopaedica, 87:2, 183-188, DOI: 10.3109/17453674.2015.1127726
To link to this article:  http://dx.doi.org/10.3109/17453674.2015.1127726
© 2016 The Author(s). Published by Taylor &
Francis on behalf of the Nordic Orthopedic
Federation.
Published online: 11 Jan 2016.
Submit your article to this journal 
Article views: 172
View related articles 
View Crossmark data
Acta Orthopaedica 2016; 87 (2): 183–188 183
Surgery of non-spinal skeletal metastases in renal cell 
carcinoma 
No effect of preoperative embolization?
Maire RATASVUORI 1,2, Niko SILLANPÄÄ 3, Rikard WEDIN 4, Clement TROVIK 5, Bjarne H HANSEN 6,   
and Minna LAITINEN 1
1 Department of Orthopaedics, Unit of Musculoskeletal Surgery, Tampere University Hospital, Tampere; 2 Department of Hand Surgery, Helsinki 
University Central Hospital, Helsinki; 3 Medical Imaging Center, Department of Radiology, Tampere University Hospital, Tampere, Finland; 4 Department 
of Orthopedics, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden; 5 Department of Orthopedics, Haukeland University Hospital, 
Bergen, Norway; 6 Department of Orthopedics, University Hospital, Aarhus, Denmark.
Correspondence: maire.ratasvuori@helsinki.fi 
Submitted 2015-08-08. Accepted 2015-10-25.
© 2016 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. This is an Open Access article distributed under the terms 
of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)
DOI 10.3109/17453674.2015.1127726
Background and purpose — Surgery for metastases of renal cell 
carcinoma has increased in the last decade. It carries a risk of 
massive blood loss, as tumors are hypervascular and the surgery 
is often extensive. Preoperative embolization is believed to facili-
tate surgery. We evaluated the effect of preoperative emboliza-
tion and resection margin on intraoperative blood loss, operation 
time, and survival in non-spinal skeletal metastases of renal cell 
carcinoma. 
Patients and methods — This retrospective study involved 144 
patients, 56 of which were treated preoperatively with emboliza-
tion. The primary outcome was intraoperative blood loss. We also 
identified factors affecting operating time and survival.
Results — We did not find statistically significant effects on 
intraoperative blood loss of preoperative embolization of skeletal 
non-spinal metastases. Pelvic localization and large tumor size 
increased intraoperative blood loss. Marginal resection compared 
to intralesional resection, nephrectomy, level of hemoglobin, and 
solitary metastases were associated with better survival.
Interpretation — Tumor size, but not embolization, was an 
independent factor for intraoperative blood loss. Marginal 
resection rather than intralesional resection should be the gold 
standard treatment for skeletal metastases in non-spinal renal 
cell carcinoma, especially in the case of a solitary lesion, as this 
improved the overall survival. 

The incidence of renal cell carcinoma (RCC) has been 
increasing (Engholm et al. 2010). RCC is characterized by an 
absence of early warning signs, especially since small tumors 
rarely produce symptoms. Thus, diagnosis can be delayed 
until the disease has metastasized (Motzer et al. 1996). The 
lung and bone are the most common sites for metastases (Han 
et al. 2003). Studies have shown that 30–40% of patients 
either have bone metastases at initial presentation of disease 
or they develop these later (Schlesinger-Raab et al. 2008, 
Woodward et al. 2011). New therapeutic options such as 
multimodal-targeted therapies have improved the treatment of 
RCC (Motzer et al. 2009). Medical therapy and radiotherapy 
are the first-line treatments for metastatic RCC. However, as 
metastases of RCC are relatively resistant to these treatments, 
surgery may be considered for skeletal metastases (Hwang et 
al. 2014). Indications for surgery with local tumor control are 
severe pain, restricted function, and impending or pathological 
fracture. According to a recent study, the proportion of 
patients with metastatic RCC who receive surgical therapy 
has increased from 4% to 6% in the last decade (Antczak et 
al. 2014).
The 5-year survival in RCC has been reported to be 77–92% 
for non-metastatic disease (Ito et al. 2015), decreasing to 
21% after diagnosis of metastases (Schlesinger-Raab et al. 
2008). The 5-year survival rate after the first operation for 
bone metastasis is 11% (Lin et al. 2007). There have been 
several studies on factors that affect survival after metastatic 
bone disease. In general, nephrectomy, the absence of visceral 
metastases, and solitary bone metastases improve survival 
(Toyoda et al. 2007, Yuasa et al. 2011, Hwang et al. 2014). 
Resection of a solitary skeletal lesion with a tumor-free margin 
appears to increase the survival rate (Baloch et al. 2000, Jung 
et al. 2003, Ratasvuori et al. 2014).
Surgical treatment of skeletal metastases from RCC carries 
a risk of massive blood loss, as tumors are hypervascular and 
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the surgery is often extensive (Wilson et al. 2010, Robial et al. 
2012). Preoperative embolization is often used; most authors 
agree that this reduces intraoperative blood loss substantially, 
making surgery easier and facilitating radical removal (Chat-
ziioannou et al. 2000, Wirbel et al. 2005, Nair et al. 2013, 
Pazionis et al. 2014). Preoperative embolization in spinal 
RCC metastases is performed frequently, despite inconsistent 
effect (Wilson et al. 2010, Robial et al. 2012, Thiex et al. 2013, 
Quraishi et al. 2013, Clausen et al. 2015). Similarly, there is 
no consensus regarding non-spinal metastases. Some stud-
ies support the belief that preoperative embolization reduces 
intraoperative blood loss (Chatziioannou et al. 2000, Wirbel et 
al. 2005). Other authors have suggested that feeding vessels 
that are clearly identified during operation are easily ligated 
(Baloch et al. 2000, Lin et al. 2007). However, most of these 
studies have included only a few patients.
We therefore determined the effect of preoperative emboli-
zation and resection margin on intraoperative blood loss and 
operating time in a large cohort of patients suffering from 
RCC with non-spinal skeletal metastases. We also investigated 
factors that influence postoperative survival. 
Patients and methods
Patients were identified from prospectively maintained data-
bases at 4 Nordic bone tumor centers (Aarhus, Denmark; 
Bergen, Norway; Stockholm, Sweden; and Tampere, Fin-
land). All the patients had had surgery for non-spinal skeletal 
metastases from RCC between October 1999 and June 2014. 
Metastatic RCC was confirmed histologically. Patient demo-
graphics included: age at presentation of pathological fracture, 
sex, comorbidities (diabetes and heart disease), American 
Society of Anesthesiologists classification, smoking habits, 
size (cm) and site of metastases (humerus, femur, pelvis), pre-
operative diagnostic procedures, hemoglobin value, number 
of skeletal metastases, and preoperative radiotherapy to the 
site of metastasis. Treatment of the primary tumor (including 
nephrectomy) and the presence of organ metastases were also 
recorded. Information on the surgical resection procedure for 
metastases, including margins of resection, methods of recon-
struction, use of tourniquet, estimated intraoperative blood 
loss (IBL), and operating time, was taken from the anesthesia 
forms. Surgical margins were defined as being intralesional 
in cases where macroscopic tumor was left—as in nailing—
or as being marginal in cases were margins were tumor-free. 
Details on the preoperative embolization procedure were 
recorded for each patient. There was no strict protocol for 
when to use preoperative embolization, but the size of the 
tumor was similar in embolized and non-embolized patients. 
If a patient underwent preoperative embolization, surgery was 
always performed within 72 h of the embolization. 
Preoperative embolization was performed via ipsilateral 
or contralateral groin puncture. Feeding arteries (1–7 arter-
ies) were accessed with microcatheters and occluded using 
various techniques, according to operator and institutional 
preferences. Detachable platinum coils, liquid embolization 
materials (acrylic glues), particles (polyvinyl alcohol), gela-
tin foam powder, or a combination of these methods were 
used. Most tumors were embolized with platinum coils, par-
ticles, or a combination of these. The success of the embo-
lization was evaluated by comparing the pre-embolization 
and post-embolization angiography images after comple-
tion of the procedure. The interventional radiologist who 
performed the procedure evaluated and classified the degree 
of devascularization as adequate (approximating more than 
75% tumor devascularization based on visual inspection of 
residual tumor enhancement), suboptimal (between 50% and 
75% devascularization), or inadequate (less than 50% devas-
cularization). We analyzed post-embolization and postopera-
tive complications.
Statistics
The primary outcome of the study was intraoperative IBL. The 
amount of intraoperative IBL was not normally distributed, 
so logarithmic transformation was used. The variables used 
in the analyses included the surgical resection margin, 
preoperative embolization, tumor size, operating time, patient 
age, comorbidities, preoperative hemoglobin value, operative 
method, and site of metastases. The Mann-Whitney U-test 
was used to evaluate differences between the groups with or 
without embolization. The operating time was also considered 
to be a dependent factor. Patient survival was assessed using 
the Kaplan-Meier method and the log-rank test, and Cox 
regression analysis was used to identify independent factors 
affecting survival. The patients for whom the date of death 
was missing—either because the patient was still alive or had 
been lost to follow-up—were censored at the last time they 
were known to be alive. If the reason for death was not cancer, 
the case was censored. Proportional hazards assumption was 
taken into account. All the variables were checked with Kaplan-
Meier curves. We plotted the cumulative hazards functions for 
the covariates and checked that lines did not cross each other. 
Statistical significance was assumed with p-values less than 
0.05. All statistical analyses were performed using IBM SPSS 
version 20.0.
Results
There were 148 operations in 144 patients, 99 male and 45 
female, with a mean age of 67 (40–90) years at first operation 
of bone metastasis. 56 of the 148 tumors (38%) were 
embolized preoperatively. Baseline data for patients with and 
without embolization were similar (Table 1). Adequate post-
embolization results were achieved in 46 cases, suboptimal 
results in 9 cases, and an inadequate result in 1 case (Figures 
1–3).
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There were 140 patients, 86 without embolization and 54 
with embolization, with information on IBL. Pelvic location 
(Mann-Whitney U-test, p < 0.01) and increasing tumor size 
(p < 0.01) were associated with increased IBL. There were 
no interactions between these variables. Factors such as age, 
liver metastasis, overall metastatic load, solitary skeletal 
metastasis, preoperative hemoglobin value, use of a tourniquet, 
operating time, operation method, resection margin, and 
preoperative embolization (including adequate cases) had no 
apparent effect on IBL (Table 2). Embolization did not have a 
statistically significant positive effect on operating time (Table 
3, see Supplementary data). Operating time was significantly 
shorter with no embolization for tumors in the humerus. 
There were no procedure-related complications during or 
after embolization. Postoperative complications were reported 
in 23 cases (16%), including tumor progression (4), nerve 
damage (1), nail failures (3), massive blood loss (1), prosthetic 
dislocations (2), wound healing problems (5), non-unions (2), 
pulmonary embolisms (3), and deep venous thrombosis (1). 
The embolization procedure did not predispose patients to 
complications. 
The median postoperative survival was 13 (0–150) months. 
Marginal resection rather than intralesional resection, 
solitary skeletal metastasis, the absence of organ metastases, 
a hemoglobin level over 100 g/L, and nephrectomy were 
Table 1. Baseline characteristics of patients with and without pre-
operative embolization for skeletal metastases from RCC
  With Without
Variable Total embolization embolization
No. of cases 148 56 92
Mean age (range)  67 67 (43–90) 67 (40–86)
Sex    
Male 102  38  64 
Female 46  18  28 
Mean ASA 2.7 2.7 2.7
Nephrectomy 98  37  61 
Organ metastases present 72  28  44 
Solitary skeletal metastases 78 33  45 
Mean tumor size (range), cm 6.4  7.1 (3–13) 6.0 (2–14)
Localization    
 Femur 82  30  52 
 Pelvis 15    9    6 
 Humerus  37  14  23 
 Other 14    5  11 
Operation method      
    Marginal resection 45  20  25 
    Intralesional resction 103  36  67 
Type of surgery    
    Tumor prosthesis 34  17  17 
Prosthesis 42  22  20 
Nailing 43  11  32 
Other 26    5  21 
Preoperative hemoglobin, g/L   121 122
 (range)  (88–197) (82–175)
Mean estimated blood loss, L 1.0  1.1 1.0
 (range)  (0.005–5.7) (0.005–12)
Mean operating time, min 135 157 120
 (range)  (65–420) (45–420)
Mean survival time (range), 
 months 12 11 (0–90)  14 (0–150)
Figure 1. Preoperative embolization performed on a tumor measuring 
13 cm located in the distal femur. Since only some residual peripheral 
tumor enhancement was seen, this was considered to be an adequate 
embolization outcome. A marginal resection and endoprosthetic 
replacement resulted in an IBL of 1.3
Figure 2. Preoperative embolization performed on a tumor with fracture 
in the proximal femur measuring 9 cm. Since a clear region of tumor 
enhancement (about 40% of the tumor) was seen in the lower parts of 
the tumor, this was considered to be a suboptimal embolization result. 
An intralesional resection and endoprosthetic replacement resulted in 
an IBL of 0.2 L.
Figure 3. Preoperative embolization performed on a proximal femur 
tumor measuring 5 cm. In the absence of any tumor enhancement, 
this was classified as an adequate embolization result. Intralesional 
resection and endoprosthetic replacement resulted in an IBL of 0.5 L.
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associated with better survival rates, but age, tumor size, 
tumor location, IBL, and preoperative embolization were not 
(Table 4, see Supplementary data). In the Cox model, solitary 
metastasis, marginal resection, hemoglobin level over 100 
g/L, and nephrectomy were independently associated with 
better survival rates (Table 5).
 
Discussion
In this retrospective study, we could not find statistically 
significant effects of preoperative embolization of skeletal non-
spinal metastases on intraoperative blood loss, irrespective of 
whether or not there was an adequate embolization result. This 
contrasts with several studies that have advocated preoperative 
embolization of bone metastases from RCC as an effective 
procedure for minimization of intraoperative bleeding (Olerud 
et al. 1993, Barton et al. 1996, Chatziioannou et al. 2000). By 
contrast, 1 study found greater IBL in embolized patients but 
suggested that this was because of patient selection bias, since 
embolization was used in larger, more central tumors and at 
sites where a tourniquet could not be applied to control IBL 
(Lin et al. 2007). In our study, tourniquet use did not have any 
apparent effect on IBL and the tumors in the embolized and 
non-embolized groups were similar in both size and location. 
The studies that have shown any effect of embolization 
on reducing IBL have had several limitations, including 
small numbers of patients and the use of statistical methods 
that were not sensitive to selection bias. Except for its 
large number of patients, the present study also had similar 
limitations, including the retrospective design and the 
possibility of selection bias. There may have been selection 
bias due to the different medical treatments, which varied 
considerably, making the numbers of patients in different 
treatment categories too small for meaningful statistical 
analysis. There may also have been bias in selecting the types 
of surgical procedures, in selecting patients for preoperative 
embolization, and in the different embolization methods. The 
strength of our study lies in the number of patients: to date, 
this is the largest published series of patients with non-spinal 
RCC metastases to be treated surgically with preoperative 
embolization. 
There was a significant correlation between tumor size and 
IBL irrespective of whether or not there was embolization. 
This has also been reported in previous studies. Pazionis et 
al. (2014) found a correlation between tumor size and IBL 
and operating time. In their case-control study, the association 
between embolization and reduced blood loss was only seen 
in femoral procedures, but in a multivariable analysis, tumor 
size was the only significant factor affecting IBL. In our study, 
pelvic location was found to be a statistically significant 
predictor of excessive blood loss, and was probably associated 
with tumor size because pelvic metastases tended to be larger. 
Although IBL is a commonly used outcome measure in 
evaluation of the efficacy of preoperative embolization, the 
amount of bleeding is difficult to quantify and may not be an 
optimal measure for evaluation of the benefits of emboliza-
tion. Although we adjusted for several confounding factors 
including resection margin, location of the metastases, and 
operation method, we did not find any statistically significant 
differences in IBL between cases with embolization or cases 
without. No benefit of preoperative embolization in facilitat-
ing the operative treatment has been convincingly shown. In 
our study, preoperative embolization did not reduce operating 
time—irrespective of the location of the tumor or the method 
of operation.
Embolization is believed to be a safe procedure. In a study 
involving 228 embolizations of a variety of tumors, only 1 
Table 2. A comparison of the factors affecting intraoperative blood loss (IBL) in the different sub-
groups of cases with and without preoperative embolization, performed using the Mann-Whitney 
U-test 
  With embolization Without embolization 
  n Median Q1–Q3 n Median Q1–Q3 p-value
Pelvis 9 1,800 (1,100–5,000) 6 1,525 (836–2,800) 0.5
Humerus 14 525 (340–625) 23 600 (200–1,020) 0.6
Femur 29 400 (275–850) 47 600 (200–900) 0.8
Prosthesis 22 500 (300–500) 20 875 (612–2,400) 0.2
Tumor prosthesis 17 600 (350–1,050) 17 400 (200–910) 0.2
Nailing and plating 9 200 (75–525) 26 375 (200–625) 0.2
Marginal resection 20 550 (350–875) 24 400 (200–725) 0.2
Intralesional removal 34 500 (300–1,650) 62 600 (238–1,210) 0.8
Table 5. Factors associated with survival (Cox regression analysis)
Variable Exp. a 95% CI p-value
Hemoglobin under 100 g/L 2.0 1.2–3.5 0.01
Intralesional removal 2.2 1.4–3.3 0.001
Multiple bone metastases 1.5 1.1–2.2 0.03
No previous nephrectomy 1.7 1.2–2.6 0.008
a Exp: HR = Hazard rate
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case with a large groin hematoma and 1 cardiac arrest due 
to general anesthesia were reported (Nair et al. 2013). In our 
study, there were no major complications related to the embo-
lization procedures. Although embolization is a safe proce-
dure, it is invasive, time-consuming, and expensive. Because 
we found similar operating times, IBL, and survival between 
groups with or without embolization, we do not recommend 
it as a routine procedure. Further research may help to define 
specific patient groups that might benefit from embolization. 
Also, the use of embolization for pain control requires further 
investigation. 
Our study confirms the results of previous studies that have 
demonstrated improved survival with a tumor-free margin of a 
metastatic lesion in RCC (Baloch et al. 2000, Lin et al. 2007, 
Fottner et al. 2010). In the present study, several confounding 
factors such as age, tumor size, and operation method were 
also taken into account. Even though radiotherapy of skeletal 
metastases can be used for pain control (Reichel et al. 2007), 
surgery is more effective in restoring function and in preventing 
local tumor progression (Laitinen et al. 2015). Moreover, the 
metastatic pattern with solitary skeletal metastasis, type of 
surgery with a tumor-free margin, and prosthetic replacement 
substantially influence the overall patient and reconstruction 
survival after surgery for RCC metastases (Jung et al. 2003, 
Fuchs et al. 2005, Alt et al. 2011, Laitinen et al. 2015). In the 
present study, there were 12 cases in which marginal resection 
was done even though patients had multiple skeletal metastases. 
Even in this limited group, marginal resection resulted in 
significantly better survival than an intralesional resection. 
The role of nephrectomy in patients with disseminated disease 
is debatable. It has been reported that nephrectomy increases 
survival in patients with skeletal metastases (Evenski et al. 
2012). This could not be analyzed in our material because 
of the number of patients in appropriate subgroups being too 
small. However, since our data show that marginal resection 
improves survival both in patients with solitary metastasis and 
in those with multiple skeletal metastases, we recommend 
that in RCC with skeletal metastases, a marginal and not an 
intralesional resection should be aimed for.
In conclusion, we were unable to show any benefit of pre-
operative embolization in preventing intraoperative bleeding 
and in improving surgical or oncological outcome. A select 
group of patients may benefit from preoperative emboliza-
tion, especially if the metastatic lesion is located in the pelvis. 
This should be addressed in future investigations. In order to 
improve overall survival, marginal resection—and not intra-
lesional resection—should be the gold standard for surgical 
management of skeletal metastases in RCC, especially if there 
are solitary lesions. 
Supplementary data
Tables 3 and 4 is available on the Acta Orthopaedica website 
at www.actaorthopaedica.org, identification number 9216.
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